Fundraising Fox
David V. Goeddel
InvestorGeneral Partner at Ponoi Capital · Partner Emeritus at The Column Group · Board director at A2 Biotherapeutics · Board director at Exonics Therapeutics · Board director at FLX Bio
Burlingame, California
Writes $100K – $5M checks · typically $1.5M
Find your path to David
222 people in our graph share verified history with David — schools, employers, funds. One of them is your warm intro.
About
The first scientist hired by Genentech, whose gene-cloning work underpinned five marketed therapeutics. Co-founded Tularik and served as its CEO; a member of the National Academy of Sciences.
Board director at A2 Biotherapeutics
Intro paths
In turn, David can intro founders to A2 Biotherapeutics's investors below.
A2 Biotherapeutics's investors · 4
Co-founders at A2 Biotherapeutics
Board director at Exonics Therapeutics
Intro paths
In turn, David can intro founders to Exonics Therapeutics's investors below.
Exonics Therapeutics's investors · 3
Board director at FLX Bio
Intro paths
In turn, David can intro founders to FLX Bio's investors below.
Experience
- The Column GroupManaging Partnercurrent2006 — present
- AmgenSenior VP2004 — 2006
- TularikFounder and CEO1991 — 2004
- GenentechDirector Molecular Biology1978 — 1993
Skills & more
+10 more
Due DiligenceTurn Around ManagementTechnology EvaluationVenture FinancingLifesciencesMolecular BiologyBioinformaticsMergersStrategic PlanningPharmaceutical IndustryFrom David's professional profile.
Deals · 5
A2 BiotherapeuticsBoard seat
via The Column Group · filed Oct 2020 · $71.5M raise
FLX BioBoard seat
via The Column Group · filed Jun 2019 · $67.1M raise
Constellation PharmaBoard seat
via The Column Group · filed Dec 2015 · $55.8M raise
Ngm BiopharmaceuticalsBoard seat
via The Column Group · filed Feb 2015 · $60M raise
Igenica BiotherapeuticsBoard seat
via The Column Group · filed Jan 2015 · $6.3M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Exonics TherapeuticsHexagon BioNeurona TherapeuticsNurix TherapeuticsThumbnail for Surrozen
Per SEC Form D filings.
Colleagues at Ponoi Capital
Network5
Investors connected to David in public investor directories — a warm-intro map.
Frequently asked questions
- Who is David V. Goeddel?
- The first scientist hired by Genentech, whose gene-cloning work underpinned five marketed therapeutics. Co-founded Tularik and served as its CEO; a member of the National Academy of Sciences.
- Where does David V. Goeddel work?
- David V. Goeddel is General Partner at Ponoi Capital and Board director at A2 Biotherapeutics and Board director at Exonics Therapeutics and Board director at FLX Bio.
- What check size does David V. Goeddel write?
- David V. Goeddel typically writes checks of $100K – $5M.
- What boards does David V. Goeddel sit on?
- David V. Goeddel holds tracked board seats at A2 Biotherapeutics, Constellation Pharma, Exonics Therapeutics, FLX Bio, FLX Bio, Hexagon Bio, Igenica Biotherapeutics, Neurona Therapeutics, Ngm Biopharmaceuticals, Nurix Therapeutics.
- Where did David V. Goeddel go to school?
- David V. Goeddel studied at University of Colorado Boulder (PhD, Biochemistry); UC San Diego (BA, Chemistry).
Same school
Also attended University of Colorado Boulder440
+ 434 more
Also attended UC San Diego577
+ 571 more
Shared employers
Also worked at Amgen188
+ 182 more
Also worked at Tularik6
Also worked at Genentech249
+ 243 more